Michael D Cameron
Overview
Explore the profile of Michael D Cameron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
3803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rangari V, OBrien E, Powers A, Slivicki R, Bertels Z, Appourchaux K, et al.
Nature
. 2025 Mar;
PMID: 40044849
The current opioid overdose epidemic highlights the urgent need to develop safer and more effective treatments for chronic pain. Cannabinoid receptor type 1 (CB1) is a promising non-opioid target for...
2.
Volf A, Brust T, Kobylski R, Czekner K, Stahl E, Cameron M, et al.
bioRxiv
. 2025 Mar;
PMID: 40027836
Abstract Figure:
3.
Bohm E, Castaneda D, Lu Q, Cameron M, Aliota M
bioRxiv
. 2025 Feb;
PMID: 39990459
Congenital Zika syndrome (CZS), the set of fetal and neonatal complications associated with Zika virus (ZIKV) infection in pregnancy, was first noted during the outbreak in the Americas in 2015-16....
4.
Chen Q, Ratnayake R, Hortiguela R, Seabra G, Cameron M, Fernando Diaz J, et al.
Bioorg Med Chem
. 2024 Nov;
95:117506.
PMID: 39492252
Microtubules, consisting of α/β-tubulin heterodimers, are prime targets for anticancer drug discovery. Gatorbulin-1 (GB1, 1a) is a recently described marine natural product that targets tubulin at a new, seventh pharmacological...
5.
Radnai L, Young E, Kikuti C, Hafenbreidel M, Stremel R, Lin L, et al.
bioRxiv
. 2024 Oct;
PMID: 39416074
Highlights: Research suggests numerous indications, from axon regeneration and cancer, would benefit from a small molecule inhibitor of non-muscle myosin II, a molecular motor that regulates the actin cytoskeleton. Current...
6.
Braunscheidel K, Voren G, Fowler C, Lu Q, Kuryatov A, Cameron M, et al.
Front Mol Neurosci
. 2024 Sep;
17:1459098.
PMID: 39346680
Background: Most smokers attempting to quit will quickly relapse to tobacco use even when treated with the most efficacious smoking cessation agents currently available. This highlights the need to develop...
7.
Trojniak A, Dang V, Czekner K, Russo R, Mather L, Stahl E, et al.
Eur J Med Chem
. 2024 Jul;
276:116627.
PMID: 38971050
Kappa opioid receptor (KOR) agonists represent promising therapeutics for pain relief due to their analgesic properties along with lower abuse potential than opioids that act at the mu opioid receptor....
8.
Kenchappa R, Radnai L, Young E, Zarco N, Lin L, Dovas A, et al.
bioRxiv
. 2024 May;
PMID: 38746089
Highlights: MT-125 is a highly specific small molecule inhibitor of non-muscle myosin IIA and IIB, is well-tolerated, and achieves therapeutic concentrations in the brain with systemic dosing.Treating preclinical models of...
9.
Tavares M, Kruger A, Yan S, Waitman K, Gomes V, de Oliveira D, et al.
Sci Rep
. 2023 Nov;
13(1):21006.
PMID: 38030668
We report a series of 1,3-diphenylureido hydroxamate HDAC inhibitors evaluated against sensitive and drug-resistant P. falciparum strains. Compounds 8a-d show potent antiplasmodial activity, indicating that a phenyl spacer allows improved...
10.
Hafenbreidel M, Pandey S, Briggs S, Arza M, Bonthu S, Fisher C, et al.
Neurobiol Learn Mem
. 2023 Nov;
206:107865.
PMID: 37995804
Preclinical studies show that inhibiting the actin motor ATPase nonmuscle myosin II (NMII) with blebbistatin (Blebb) in the basolateral amgydala (BLA) depolymerizes actin, resulting in an immediate, retrieval-independent disruption of...